A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)

NCT06103825 | Completed Phase 3

• 1 other identifier: IGN-B0301-03
• Study Type: interventional
• Target: 204
• Locations: 1 country
• Sites: 26

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of 12-week solriamfetol administration in the treatment of EDS in patients with OSA from China, using a randomized, double-blind, placebo-controlled, multi-center, parallel-design.

Conditions

Sleep Apnea, Obstructive; Excessive Daytime Sleepiness

Outcome Measures

Primary Outcomes (2)

• To evaluate the effect of solriamfetol compared to placebo among patients with OSA in change from baseline to Week 12 in the mean MWT sleep latency (minutes, (determined from the first four 40-minute trials of the MWT)

  Change from baseline in mean MWT sleep latency (minutes, determined from the first four 40-minute trials of the MWT) to Week 12

  From enrollment to the end of treatment at 12 weeks

• To evaluate the effect of solriamfetol compared to placebo among patients with OSA in change from baseline to Week 12 in ESS scores

  Change from baseline in ESS total score to Week 12 Epworth Sleepiness Scale (ESS): ESS score ranges from 0 to 24 (inclusive), with higher score denoting greater degrees of sleepiness

  From enrollment to the end of treatment at 12 weeks

Secondary Outcomes (7)

• Key Secondary Study Objective: To compare treatment with solriamfetol versus placebo on the percentage of participants reported as improved (minimally, much, very much) in PGIc at Week 12 among patients with OSA

  From enrollment to the end of treatment at 12 weeks

• Other Secondary Study Objective 1:To evaluate the effect of solriamfetol compared to placebo among patients with OSA in change from baseline to Week 2 and Week 5 in the mean MWT sleep latency

  From enrollment to the end of treatment at the 2- and 5-week

• Other Secondary Study Objective 2: To evaluate the effect of solriamfetol compared to placebo among patients with OSA in change from baseline to Week 2, 5 and 8 in ESS score

  From enrollment to the end of treatment at the 2- ,5- and 8-week

• Other Secondary Study Objective 3: To compare treatment with solriamfetol versus placebo on the percentage of participants reported as improved (minimally, much, very much) in PGIc at Week 2, 5 and 8 among patients with OSA

  From enrollment to the end of treatment at the 2- ,5- and 8-week

• Other Secondary Study Objective 4: To compare treatment with solriamfetol versus placebo on the percentage of participants rated as improved (minimally, much, very much) in CGIc at Week 12 among patients with OSA

  From enrollment to the end of treatment at 12 weeks

Study Arms (2)

Strengths of solriamfetol (JZP-110) strengths: 37.5 mg，75 mg, 150 mg

EXPERIMENTAL

subject will first enter a 2-week Titration Phase, during which the initial dose will be 37.5mg. The dose will be increased from 37.5mg QD to 75mg QD after 3 days, and then to 150mg QD at the first day of the second week if well-tolerated. subjects will then enter the 10-week Maintenance Phase on 150mg QD if well-tolerated. If a subject tolerability issues after titration up to 150mg at the second week, the dose can be reduced to 75mg QD following instructions of the investigators. This subject will then enter the 10-week Maintenance Phase on 75mg QD. If a subject experiences tolerability issues after titration up to 75mg at the first week, the dose can be reduced to 37.5mg QD following instructions of the investigators. The dose will be increased to 75mg QD again at the first day of the second week. Subject will then enter the 10-week Maintenance Phase on 75mg QD if well-tolerated. All subjects should be maintained on either 75mg QD or 150mg QD during the Maintenance Phase.

Drug: Solriamfetol

matching Placebo

PLACEBO COMPARATOR

Drug: Placebo

Interventions

Solriamfetol DRUG

solriamfetol : QD，PO，Day 1-Day 84；

Strengths of solriamfetol (JZP-110) strengths: 37.5 mg，75 mg, 150 mg

Placebo DRUG

Placebo :QD，PO，Day 1-Day 84

matching Placebo

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female between 18 to 75 years of age, inclusive.
• Diagnosis of OSA according to the International Classification of Sleep Disorders, 3rd edition (ICSD-3) criteria.
• Patients with OSA may be considered for enrollment if they meet one of the following criteria:
• Use of a primary therapy for OSA (i.e., positive airway pressure (PAP), oral pressure therapy, oral appliance, or upper airway stimulator) on at least 1 night per week, or
• History of at least 1 month of an attempt to use one or more primary OSA therapies with at least one documented adjustment that was made in an attempt to optimize the primary OSA therapy, or participants who have never used and refuse to use a primary OSA therapy, or
• History of a surgical intervention intended to treat OSA symptoms.
• A stable level of compliance with a primary OSA therapy for at least 1 month prior to the baseline visit as follows:
• A stable level of use of a primary OSA therapy, or
• A lack of use of a primary OSA therapy either following a history of attempted use, or have never used before, or
• A history of a surgical intervention intended to treat OSA symptoms.
• Baseline ESS score no less than 10 points (≥ 10 points).
• Baseline MWT mean sleep latency \< 30 minutes (documented by the mean of the first four 40-minute trials of the MWTs).
• Usual nightly total sleep time of at least 6 hours (≥ 6 hours).
• Body mass index (BMI) from18 kg/m2 to \< 45 kg/m2.
• Female participants must have negative pregnancy test results at the screening and baseline visits; all participants must consent to use a medically acceptable method of contraception throughout the entire study period and for 30 days after the study is completed.

You may not qualify if:

• Female participants who are pregnant or lactating.
• Usual bedtime later than 1 a.m. (01:00).
• Occupation requiring nighttime shift work or variable shift work.
• Any other clinically relevant medical, behavioral, or psychiatric disorders other than OSA that is associated with excessive sleepiness.
• History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorder, or other psychotic disorders according to DSM-5 criteria, or presence of significant suicidality.
• History or presence of any acutely unstable medical condition, behavioral or cognitive impairment, or any medical condition or surgical history that could affect the safety of the participant or interfere with study efficacy, safety and PK assessments, or the ability of the participant to complete the study per the judgment of the investigator.
• History of the bariatric surgery within the past year or a history of any gastric bypass procedure.
• Presence of renal impairment or calculated creatinine clearance less than 60 mL/min at screening, which is calculated using the following formula: CLcr (mL/min) = (140 - age \[years\]) x body weight (kg) x (0.85, if female))/(72 x serum creatinine value \[mg/dL\]), if serum creatinine is expressed in µmol/L, the value should be divided by 88.4 to convert µmol/L to mg/dL.
• Clinically significant ECG abnormality in the opinion of the investigator would preclude participation in the study.
• Presence of significant cardiovascular disease at screening, including but not limited to: myocardial infarction within the past year, unstable angina pectoris, symptomatic congestive heart failure \[(American College of Cardiology/American Heart Association (ACC/AHA) Stage C or D)\], revascularization procedures within the past year, ventricular cardiac arrhythmia requiring an automatic implantable cardioverter defibrillator (AICD) or medication therapy, uncontrolled hypertension, systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 95 mmHg (at Screening, or across Baseline measures according to protocol specifications), or any significant cardiovascular condition that in the investigator's opinion may jeopardize participant's safety in the study.
• Laboratory value(s) outside the laboratory reference range that are considered to be clinically significant and may affect the safety of the participant per the judgment of the investigator (including clinical chemistry, hematology, and urinalysis) (Note: Screening labs may be repeated once).
• Excessive caffeine use one week prior to the baseline assessments, or anticipated excess caffeine use during the study, defined as greater than 600 mg caffeine per day (\>600 mg/day).
• Use of any over-the-counter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness within a time period prior to the baseline visit corresponding to at least five half-lives of the drug(s) or planned use of such drug(s) at some point throughout the duration of the study. Examples of excluded medications include OTC sleep aids or stimulants (e.g., pseudoephedrine), methylphenidate, amphetamines, modafinil, 2-acetamide, sodium oxybate, pemoline, trazodone, hypnotics, benzodiazepines, barbiturates, and opioids, and any traditional Chinese medicine that may affect sleep. Medications should be discontinued such that the participant has returned to his/her baseline level of daytime sleepiness at least 7 days prior to the baseline visit, in the opinion of the investigator.
• Use of a monoamine oxidase inhibitor (MAOI) in the past 14 days or five half-lives (whichever is longer) prior to the baseline visit or plans to use an MAOI during the study.
• Received an investigational drug or device in the past 30 days or five half-lives (whichever is longer) prior to the baseline visit, or plans to use an investigational drug (other than the investigational drug) or investigational medical devices during the study

Sponsors & Collaborators

• Ignis Therapeutics (Suzhou) Limited: lead

Study Sites (26)

Shanghai Sixth People's Hospital

Shanghai, Shanghai Municipality, China

Location

Beijing TianTan Hospital Capital Medical University

Beijing, China

Location

China-Japan friendship Hospital

Beijing, China

Location

Peking University Sixth Hospital

Beijing, China

Location

XuanWu Hospital Capital Medical University

Beijing, China

Location

The first hospital of Jilin University

Changchun, China

Location

Xiangya Hospital Central South University

Changsha, China

Location

ChongQing University three gorges Hospital

Chongqing, China

Location

The Hospital Group of the First Affiliated Hospital of CQMU

Chongqing, China

Location

GanSU Provincial Hospital

Gansu, China

Location

The first affiliated hospital of Guangzhou Medical University

Guangzhou, China

Location

The first affiliated hospital of JiNan University

Guangzhou, China

Location

Hangzhou seventh People's Hospital

Hangzhou, China

Location

The first hospital of Hebei Medical University

Hebei, China

Location

Huai'an First People's Hospital

Huai'an, China

Location

The Second Affiliated Hospital of Nanchang University

Nanchang, China

Location

The Fitst Affiliated Hospital of NingBo University

Ningbo, China

Location

ShanDong Provincial QianFoShan Hospital

Shandong, China

Location

HuaShan Hospital FuDan University

Shanghai, China

Location

First hospital of ShanXi Medical University

Shanxi, China

Location

Second hospital of Shanxi Medical University

Shanxi, China

Location

ShenZhen People's Hospital

Shenzhen, China

Location

West China fourth Hospital Sichuan University

Sichuan, China

Location

The Second Affiliated Hospital of Suzhou University

Suzhou, China

Location

Yan'an University Xianyang Hospital

Xianyang, China

Location

The First People's Hospital of YunNan Province

Yunnan, China

Location

Related Publications (1)

• Cheng H, Deng L, Meng Z, Zhang W, Chen T, Chen R, Tang S, Lv Y, Su X, Liu Z, Zhang X, Wang X, Mao H, Zhang N, Yu H, Pan J, Xie Y, Tang J, Yin S, Wang Z, Tong M, Zhan S, Wang C, Wang B, Zhang W, Mi W, Lu L. Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial. CNS Drugs. 2026 Jan;40(1):83-98. doi: 10.1007/s40263-025-01232-1. Epub 2025 Oct 23.

  PMID: 41128833 DERIVED

MeSH Terms

Conditions

Sleep Apnea, Obstructive; Disorders of Excessive Somnolence

Interventions

solriamfetol

Condition Hierarchy (Ancestors)

Sleep Apnea Syndromes; Apnea; Respiration Disorders; Respiratory Tract Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases; Mental Disorders

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 27, 2023
• First Posted: October 27, 2023
• Study Start: August 1, 2023
• Primary Completion: July 20, 2024
• Study Completion: August 19, 2024
• Last Updated: March 3, 2025

Record last verified: 2024-10

Locations

CN (26)